General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics.

Author: HasegawaY, InukaiT, KurodaK, NakaoK, NishimoriT, NishimuraT, SakonjyoH, TakemoriE, YamamotoS

Overview

Benazepril hydrochloride, a novel angiotensin I converting enzyme inhibitor, has minimal effects on cardiovascular, visceral, and renal functions in experimental animals. At a high dose of 100 mg/kg p.o., it had little influence on respiration, heart rate, ECG, spontaneous uterine motility, charcoal transportation, and gastrointestinal tract motility. Benazepril hydrochloride also showed no effect on blood glucose and cholesterol levels in alloxan-induced diabetic rats, but decreased triglyceride and total cholesterol levels in normotensive rats. It significantly decreased aortic atherosclerosis in cholesterol-fed rabbits. Overall, benazepril hydrochloride appears to be a safe and well-tolerated cardiovascular drug.

Paper Details　

Original Abstract of the Article :

The effects of benazepril hydrochloride (CGS 14824 A, CAS 86541-74-4), a novel angiotensin I converting enzyme inhibitor, on cardiovascular, visceral and renal functions and on hemodynamics, were studied in various experimental animals. Even at a high dose of 100 mg/kg p.o. benazepirl hydrochloride ...See full text at original site

Dr.Camel's Paper Summary Blog

Benazepril Hydrochloride: A Novel Angiotensin-Converting Enzyme Inhibitor

In the vast desert of [cardiovascular research], we are constantly searching for new oases of effective treatments. This study introduces a novel [angiotensin-converting enzyme inhibitor], [benazepril hydrochloride], and explores its effects on various physiological systems in animal models.

Benazepril Hydrochloride: A Safe and Effective Treatment Option

The results of this extensive investigation demonstrate that [benazepril hydrochloride] exhibits a favorable safety profile across a wide range of doses. It does not appear to interfere with [respiration], [heart rate], [ECG], or [smooth muscle function]. Furthermore, it does not cause [gastric irritation] or disrupt [gastrointestinal motility]. Although it showed [hemolytic activity] at high concentrations, it did not affect [red blood cell fragility] or [platelet aggregation] in animal models. These findings suggest that [benazepril hydrochloride] has the potential to be a safe and effective treatment option for [cardiovascular conditions].

Dr.Camel's Conclusion

This research provides a comprehensive overview of the pharmacological properties of [benazepril hydrochloride]. Its demonstrated safety and potential efficacy in [cardiovascular conditions] make it a valuable addition to the therapeutic arsenal. However, as with any medication, the decision to use [benazepril hydrochloride] should be made in consultation with a healthcare professional, taking into account individual patient factors and potential risks.